CXCR4-Targeted Therapy

About Nanoligent

Nanoligent is a private, preclinical-stage biotech founded in 2017 as a spin-off from the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. The company's core asset is its 'Precision Nanotherapy Platform,' which creates humanized, self-assembling protein nanoparticle conjugates for targeted drug delivery in cancer. Its lead program targets CXCR4 to halt tumor growth and metastasis and is in preclinical development. The company is backed by non-dilutive funding from Spanish and European public entities, positioning it to advance its first candidate toward clinical trials.

Therapeutic Areas